|
|
Volumn 18, Issue 12, 2012, Pages 1717-
|
|
Lessons from vaccine history
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCG VACCINE;
DENGUE VACCINE;
EPITOPE;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
IMMUNOLOGICAL ADJUVANT;
INFLUENZA VACCINE;
MALARIA VACCINE;
VACCINE;
YELLOW FEVER VACCINE;
ANTIBODY RESPONSE;
ANTIGENICITY;
CELLULAR IMMUNITY;
DENGUE;
DRUG DESIGN;
DRUG EFFICACY;
EDITORIAL;
GROUPS BY AGE;
HIGH RISK POPULATION;
HUMAN;
INNATE IMMUNITY;
MALARIA;
MUTATION;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTECTION;
SEROTYPE;
T LYMPHOCYTE;
VACCINATION;
CLINICAL TRIALS AS TOPIC;
COMMUNICABLE DISEASE CONTROL;
DRUG DESIGN;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
VACCINES;
|
|
EID: 84870930569
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm.3039 Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|